NCT04733417 is a Phase 2 clinical trial of SHR6390 in Advanced Breast Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT04733417?

NCT04733417 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT04733417?

Interventions in NCT04733417: SHR6390, famitinib.

What condition does NCT04733417 study?

NCT04733417 studies Advanced Breast Cancer, Metastatic Breast Cancer.

Is NCT04733417 still recruiting?

NCT04733417 is currently status unknown. Last updated 13 April 2023.

Last reviewed 2023-04-13 · How we verify

NCT04733417

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Status unknown Phase 2 Last updated 13 April 2023

What this trial tests

Phase 2 trial testing SHR6390 in Advanced Breast Cancer in 35 participants. Status unknown.

Timeline

26 May 2021

Primary endpoint
30 August 2022

30 September 2023

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	26 May 2021
Primary completion	30 August 2022
Estimated completion	30 September 2023
Sites	1 location across China

Drugs / interventions tested

SHR6390 — full drug profile →
famitinib — full drug profile →

Conditions studied

Advanced Breast Cancer — all drugs for Advanced Breast Cancer →
Metastatic Breast Cancer — all drugs for Metastatic Breast Cancer →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 75, female only, with Advanced Breast Cancer or Metastatic Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is being conducted to assess the efficacy and safety of SHR6390 combined with famitinib in the treatment of advanced or metastatic breast cancer that progress in 1-2 line endocrine therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis.
Fernández-Nogueira P, Fuster G, Gutierrez-Uzquiza Á, Gascón P, et al · · 2021 · cited 43× · PMID 34201840 · DOI 10.3390/cancers13133146

Verify or expand the search:

Other trials of SHR6390

Trials testing the same drug.

NCT05515289 — Study of SHR6390 in Renal Insufficiency and Healthy Subjects · Phase 1 · unknown
NCT05205200 — Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02 · Phase 2 · recruiting
NCT05176080 — Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer · Phase 1, PHASE2 · terminated
NCT04842617 — Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive · Phase 3 · active not recruiting
NCT04667156 — Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects · Phase 1 · completed

Other recruiting trials for Advanced Breast Cancer

Currently open trials in the same condition.

NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07318805 — A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07259226 — Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers · Phase 2 · recruiting
NCT06982521 — Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI · Phase 3 · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04733417 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 13 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04733417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing